Impaired fasting glucose levels in overweight or obese subjects for screening of type 2 diabetes in Korea

被引:4
|
作者
Lee, Jin-Hee [1 ]
Chon, Suk [2 ]
Cha, Seon-Ah [3 ]
Lim, Sun-Young [1 ]
Kim, Kook-Rye [3 ]
Yun, Jae-Seung [3 ]
Rhee, Sang Youl [2 ]
Yoon, Kun-Ho [1 ,4 ]
Ahn, Yu-Bae [3 ]
Woo, Jeong-Taek [2 ]
Ko, Seung-Hyun [3 ]
机构
[1] Catholic Univ Korea, Catholic Inst Smart Healthcare Ctr, Inst Biomed Ind, Seoul, South Korea
[2] Kyung Hee Univ, Dept Endocrinol & Metab, Sch Med, Seoul, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Endocrinol & Metab,St Vincents Hosp, 93 Jungbu Daero, Suwon 16247, South Korea
[4] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
来源
KOREAN JOURNAL OF INTERNAL MEDICINE | 2021年 / 36卷 / 02期
关键词
Diabetes mellitus; type; 2; Prediabetic state; Impaired fasting glucose; Overweight; Hemoglobin A1c; LIFE-STYLE INTERVENTION; FOLLOW-UP; TOLERANCE; POPULATION; REDUCTION; DIAGNOSIS; MELLITUS; RISK;
D O I
10.3904/kjim.2019.171
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: We examined the concordance rate among fasting plasma glucose (FPG), 2-hour post-challenge glucose (2hr PG), and hemoglobin A1c (HbA1c) in the diagnosis of diabetes in a population with a high-risk for type 2 diabetes mellitus (T2DM) in Korea. Methods: Among the participants from the Korean Diabetes Prevention Study, individuals with FPG >= 100 mg/dL, body mass index (BMI) >= 23.0 kg/m(2), and no previous history of T2DM were consecutively enrolled after a 75 g glucose tolerance test. We analyzed the differences in the clinical characteristics in subjects with stage 1 (FPG, 100 to 109 mg/dL) and stage 2 (FPG, 110 to 125 mg/dL) impaired fasting glucose (IFG). Results: Of 1,637 participants, 27.2% had T2DM and 59.3% had IFG and/or impaired glucose tolerance (IGT). The mean age was 55.0 +/- 8.1 years and the mean BMI was 26.3 +/- 2.7 kg/m(2). Based on FPG criteria, 515 (31.4%) and 352 (21.5%) subjects were classified as having stage 1 and stage 2 IFG, respectively. The 19.0% of stage 1 and 43.5% of stage 2 subjects showed 2hr PG levels in the diabetic range. Even for those in the normal FPG range, 63 (9.5%) participants showed a 2hr PG level of >= 200 mg/dL. Of 446 subjects with newly-diagnosed diabetes, 340 (76.2%) showed FPG levels < 126 mg/dL. Conclusions: The oral glucose tolerance test should be actively considered for Korean adults who are overweight or obese with the IFG range (FPG, 100 to 125 mg/dL) to allow for early detection of diabetes and prompt intervention.
引用
收藏
页码:382 / +
页数:13
相关论文
共 50 条
  • [31] Relation between Family History of Neoplasms and Impaired Fasting Glucose in Obese-Overweight Non-Diabetic Subjects
    Seghieri, Giuseppe
    Fabbri, Gianna
    Tesi, Federica
    Anichini, Roberto
    [J]. DIABETES, 2012, 61 : A662 - A662
  • [32] Can HbA1c assist in diagnosis of type 2 diabetes in subjects with impaired fasting glucose?
    Manley, Susan E.
    Baskar, Varadarajan
    Nightingale, Peter G.
    Stratton, Irene M.
    Round, Rachel A.
    Smith, Janet M.
    Gough, Stephen G.
    [J]. DIABETES, 2007, 56 : A239 - A239
  • [33] Positive effect of Orlistat on controlling blood glucose levels in overweight and obese patients with Type 2 diabetes
    Valensi, P
    Eschwège, E
    Drouin, P
    Gin, H
    Joubert, J
    Guy-Grand, B
    [J]. DIABETOLOGIA, 2002, 45 : A220 - A220
  • [34] Effect of orlistat on post-prandial glucose levels in overweight or obese patients with type 2 diabetes
    Hanefeld, M
    [J]. DIABETES, 2002, 51 : A99 - A100
  • [35] GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects
    Fernandez-Garcia, Jose C.
    Murri, Mora
    Coin-Aragueez, Leticia
    Alcaide, Juan
    El Bekay, Rajaa
    Tinahones, Francisco J.
    [J]. CLINICAL ENDOCRINOLOGY, 2014, 80 (05) : 671 - 676
  • [36] A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes
    Marbury, T. C.
    Schwartz, S.
    Rosenberg, M. A.
    Jarlwala, N.
    Becker, R. H. A.
    Johnston, P. S.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (05) : 282 - 288
  • [37] Evaluatioin of the safety, efficacy and tolerability of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes
    Marbury, T
    Schwartz, S
    Rosenberg, M
    Johnston, P
    Jariwala, N
    Shukla, U
    Becker, R
    Saoud, J
    [J]. DIABETES, 2003, 52 : A451 - A452
  • [38] Adipokine Pattern in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance in Comparison to Normal Glucose Tolerance and Diabetes
    Toenjes, Anke
    Fasshauer, Mathias
    Kratzsch, Juergen
    Stumvoll, Michael
    Blueher, Matthias
    [J]. PLOS ONE, 2010, 5 (11):
  • [39] Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance
    Mannucci, E
    Ognibene, A
    Sposato, I
    Brogi, M
    Gallori, G
    Bardini, G
    Cremasco, F
    Messeri, G
    Rotella, CM
    [J]. ACTA DIABETOLOGICA, 2003, 40 (04) : 181 - 186
  • [40] Coffee consumption and incidence of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes: the Hoorn Study
    R. M. van Dam
    J. M. Dekker
    G. Nijpels
    C. D. A. Stehouwer
    L. M. Bouter
    R. J. Heine
    [J]. Diabetologia, 2004, 47 : 2152 - 2159